These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 31233480)

  • 1. Outcomes of Liver Transplantation for Hepatocellular Carcinoma Beyond the University of California San Francisco Criteria: A Single-center Experience.
    Victor DW; Monsour HP; Boktour M; Lunsford K; Balogh J; Graviss EA; Nguyen DT; McFadden R; Divatia MK; Heyne K; Ankoma-Sey V; Egwim C; Galati J; Duchini A; Saharia A; Mobley C; Gaber AO; Ghobrial RM
    Transplantation; 2020 Jan; 104(1):113-121. PubMed ID: 31233480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
    Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
    Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
    Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
    Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
    Lee DD; Samoylova M; Mehta N; Musto KR; Roberts JP; Yao FY; Harnois DM
    Liver Transpl; 2019 Feb; 25(2):228-241. PubMed ID: 30198150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.
    Kim Y; Stahl CC; Makramalla A; Olowokure OO; Ristagno RL; Dhar VK; Schoech MR; Chadalavada S; Latif T; Kharofa J; Bari K; Shah SA
    Surgery; 2017 Dec; 162(6):1250-1258. PubMed ID: 29033224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol.
    Sinha J; Mehta N; Dodge JL; Poltavskiy E; Roberts J; Yao F
    Hepatology; 2019 Oct; 70(4):1185-1196. PubMed ID: 30779440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma.
    Piardi T; Gheza F; Ellero B; Woehl-Jaegle ML; Ntourakis D; Cantu M; Marzano E; Audet M; Wolf P; Pessaux P
    Ann Surg Oncol; 2012 Jun; 19(6):2020-6. PubMed ID: 22179632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
    Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
    Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
    World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
    Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
    Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
    Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
    Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation.
    Kim PT; Onaca N; Chinnakotla S; Davis GL; Jennings LW; McKenna GJ; Ruiz RM; Levy MF; Goldstein R; Klintmalm GB
    Clin Transplant; 2013; 27(2):311-8. PubMed ID: 23351129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Downstaging and Bridging of Hepatocellular Carcinoma on Survival Following Liver Transplant: A Single Center Experience.
    Al Sebayel MI; Elsiesy H; Al-Hamoudi W; Alabbad S; ElSheikh Y; Elbeshbeshy H; Salih I; Yousif S; Saleh Y; Eldali A; Abaalkhail FA
    Exp Clin Transplant; 2017 Mar; 15(Suppl 2):7-11. PubMed ID: 28301992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome comparisons among the Hangzhou, Chengdu, and UCSF criteria for hepatocellular carcinoma liver transplantation after successful downstaging therapies.
    Lei J; Yan L
    J Gastrointest Surg; 2013 Jun; 17(6):1116-22. PubMed ID: 23325342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time.
    Decaens T; Roudot-Thoraval F; Hadni-Bresson S; Meyer C; Gugenheim J; Durand F; Bernard PH; Boillot O; Sulpice L; Calmus Y; Hardwigsen J; Ducerf C; Pageaux GP; Dharancy S; Chazouilleres O; Cherqui D; Duvoux C
    Liver Transpl; 2006 Dec; 12(12):1761-9. PubMed ID: 16964590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Timing of Liver Transplantation Following Downstaging: Wait of Not to Wait?
    Ersan V; Barut B; Yilmaz S
    J Gastrointest Cancer; 2020 Dec; 51(4):1152-1156. PubMed ID: 32856230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.
    Grąt M; Kornasiewicz O; Lewandowski Z; Hołówko W; Grąt K; Kobryń K; Patkowski W; Zieniewicz K; Krawczyk M
    World J Surg; 2014 Oct; 38(10):2698-707. PubMed ID: 24858191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.